Abstract
T-cell activation is dependent on signals delivered through the antigen-specific T-cell receptor and accessory receptors on T-cells. Integration of signals through this family of costimulatory and inhibitory receptors and their ligands regulates the balance between T-cell activation, tolerance, and immunopathology. Programmed death 1 (PD-1) and its ligands, PD-L1 and PD-L2, deliver inhibitory signals and exert a vital and diverse range of immunoregulatory roles in T-cell activation, tolerance, and immune-mediated tissue damage. In this review, we revisit current understanding of the immunoregulatory functions of PD-1 and its ligands and their involvement in immune-mediated diseases.
Keywords: Alzheimer's disease, autoimmunity, costimulation, HIV infection, immune tolerance, multiple sclerosis, PD-1, PD-L1, T-cell activation, immune system, microbial pathogens, antigens, antigenic peptide/major histocompatibility complex, costimulatory signals, phenotype
Current Molecular Medicine
Title: The PD-1/PD-L1 Pathway in Human Pathology
Volume: 12 Issue: 3
Author(s): M. Saresella, V. Rainone, N. M. Al-Daghri, M. Clerici and D. Trabattoni
Affiliation:
Keywords: Alzheimer's disease, autoimmunity, costimulation, HIV infection, immune tolerance, multiple sclerosis, PD-1, PD-L1, T-cell activation, immune system, microbial pathogens, antigens, antigenic peptide/major histocompatibility complex, costimulatory signals, phenotype
Abstract: T-cell activation is dependent on signals delivered through the antigen-specific T-cell receptor and accessory receptors on T-cells. Integration of signals through this family of costimulatory and inhibitory receptors and their ligands regulates the balance between T-cell activation, tolerance, and immunopathology. Programmed death 1 (PD-1) and its ligands, PD-L1 and PD-L2, deliver inhibitory signals and exert a vital and diverse range of immunoregulatory roles in T-cell activation, tolerance, and immune-mediated tissue damage. In this review, we revisit current understanding of the immunoregulatory functions of PD-1 and its ligands and their involvement in immune-mediated diseases.
Export Options
About this article
Cite this article as:
Saresella M., Rainone V., M. Al-Daghri N., Clerici M. and Trabattoni D., The PD-1/PD-L1 Pathway in Human Pathology, Current Molecular Medicine 2012; 12 (3) . https://dx.doi.org/10.2174/156652412799218903
DOI https://dx.doi.org/10.2174/156652412799218903 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of the α7 Nicotinic Acetylcholine Receptor and RIC-3 in the Cholinergic Anti-inflammatory Pathway
Central Nervous System Agents in Medicinal Chemistry Autoantibodies in Autoimmune Diseases
Current Pharmaceutical Design Potential Applications of Vasoactive Intestinal Peptide-Based Therapies on Transplantation
Endocrine, Metabolic & Immune Disorders - Drug Targets Mitochondrial Dysfunction in the Pathophysiology of Bipolar Disorder: Effects of Pharmacotherapy
Mini-Reviews in Medicinal Chemistry Ocular Inflammatory Diseases: Molecular Pathogenesis and Immunotherapy
Current Molecular Medicine Relationship Between the Chemokine Receptor CCR5 and Microglia in Neurological Disorders: Consequences of Targeting CCR5 on Neuroinflammation, Neuronal Death and Regeneration in a Model of Epilepsy
CNS & Neurological Disorders - Drug Targets Natalizumab Changes the Peripheral Profile of the Th17 Panel in MS Patients: New Mechanisms of Action
CNS & Neurological Disorders - Drug Targets Genetically-Modified Hematopoietic Stem Cells and their Progeny for Widespread and Efficient Protein Delivery to Diseased Sites: The Case of Lysosomal Storage Disorders
Current Gene Therapy The Role of VE-cadherin in Blood-brain Barrier Integrity Under Central Nervous System Pathological Conditions
Current Neuropharmacology Inflammatory Signaling Networks as Targets for Pharmacological Intervention of Chronic Diseases
Current Signal Transduction Therapy Modulation of Apoptosis: New Opportunities for Drug Discovery to Treat Autoimmune Thyroiditis
Recent Patents on Inflammation & Allergy Drug Discovery DNA Vaccine and the CNS Axonal Regeneration
Current Pharmaceutical Design Metformin, A New Era for an Old Drug in the Treatment of Immune Mediated Disease?
Current Drug Targets Prostanoid Receptors as Possible Targets for Anti-Allergic Drugs: Recent Advances in Prostanoids on Allergy and Immunology
Current Drug Targets Quantifying Gp96/Grp94 Complexes Preparations for Vaccines: a Key Step Often Inaccurate
Current Medicinal Chemistry Selective Activation of Intracellular Signalling Pathways in Dendritic Cells for Cancer Immunotherapy
Anti-Cancer Agents in Medicinal Chemistry The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases
Current Medicinal Chemistry Cannabinoid Modulation of Neuroinflammatory Disorders
Current Neuropharmacology Implication of CD154/CD40 Interaction in Healthy and Autoimmune Responses
Current Immunology Reviews (Discontinued) NMNAT Expression and its Relation to NAD Metabolism
Current Medicinal Chemistry